Last reviewed · How we verify

Teneligliptin Placebo Oral Tablet

Handok Inc. · Phase 3 active Small molecule

Teneligliptin Placebo Oral Tablet is a DPP-4 inhibitor Small molecule drug developed by Handok Inc.. It is currently in Phase 3 development for Type 2 diabetes.

Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases the levels of incretin hormones, enhancing glucose-dependent insulin secretion.

Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases the levels of incretin hormones, enhancing glucose-dependent insulin secretion. Used for Type 2 diabetes.

At a glance

Generic nameTeneligliptin Placebo Oral Tablet
SponsorHandok Inc.
Drug classDPP-4 inhibitor
TargetDPP-4
ModalitySmall molecule
Therapeutic areaDiabetes
PhasePhase 3

Mechanism of action

By inhibiting DPP-4, teneligliptin reduces the breakdown of incretin hormones, leading to increased insulin secretion in response to meals and decreased glucagon secretion. This results in improved glycemic control and reduced glucose production in the liver.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Teneligliptin Placebo Oral Tablet

What is Teneligliptin Placebo Oral Tablet?

Teneligliptin Placebo Oral Tablet is a DPP-4 inhibitor drug developed by Handok Inc., indicated for Type 2 diabetes.

How does Teneligliptin Placebo Oral Tablet work?

Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases the levels of incretin hormones, enhancing glucose-dependent insulin secretion.

What is Teneligliptin Placebo Oral Tablet used for?

Teneligliptin Placebo Oral Tablet is indicated for Type 2 diabetes.

Who makes Teneligliptin Placebo Oral Tablet?

Teneligliptin Placebo Oral Tablet is developed by Handok Inc. (see full Handok Inc. pipeline at /company/handok-inc).

What drug class is Teneligliptin Placebo Oral Tablet in?

Teneligliptin Placebo Oral Tablet belongs to the DPP-4 inhibitor class. See all DPP-4 inhibitor drugs at /class/dpp-4-inhibitor.

What development phase is Teneligliptin Placebo Oral Tablet in?

Teneligliptin Placebo Oral Tablet is in Phase 3.

What are the side effects of Teneligliptin Placebo Oral Tablet?

Common side effects of Teneligliptin Placebo Oral Tablet include Nausea, Diarrhea, Headache, Injection site reaction, Hypoglycemia.

What does Teneligliptin Placebo Oral Tablet target?

Teneligliptin Placebo Oral Tablet targets DPP-4 and is a DPP-4 inhibitor.

Related